UBS raised the firm’s price target on Novo Nordisk to DKK 1,100 from DKK 795 and keeps a Neutral rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- 2seventy Bio announces sale of Hemophilia A candidate for up to $40M
- Novo Nordisk Halts Trial, Faces Financial Setback
- Novo Nordisk kidney failure only ‘modest negative,’ says BMO Capital
- Novo Nordisk stops CLARION-CKD trial, recognizes DKK 5.7B impairment loss
- Novo Nordisk’s FLOW data supportive of ‘growing moat’, says BMO Capital
Questions or Comments about the article? Write to editor@tipranks.com